Emcure Pharmaceuticals Limited

BSE: 544210 NSE: EMCURE
Emcure Pharmaceuticals Limited - pharma in Pune, Maharashtra, India. FY 2026 financials & compliance.
CIN L24231PN1981PLC024251 Incorporated 16 April 1981 ROC Pune HQ Pune, Maharashtra, India
Active Listed - NSE: EMCURE · BSE: 544210 Public Limited Company pharma Fortune India 500 · #313 Nifty 500
Data last updated
Market Cap
₹42,044 Cr
EMCURE · NSE
Share Price
₹2,216.20
-2.80% today
Revenue
₹9,204 Cr
FY 2025-26 · +16.6% YoY
EBITDA
₹1,714 Cr
Margin 18.6%
Net Profit
₹945 Cr
FY 2025-26 · +48.3% YoY
P/E (TTM)
37.7x
P/B 7.9x
ROE
20.0%
ROCE 23.1%
Debt / Equity
0.27
Interest cover 11.1x

About Emcure Pharmaceuticals Limited

Data last updated:

Emcure Pharmaceuticals Limited is a public limited company based in Pune, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 April 1981 and has been in existence for over 45 years.

Emcure Pharmaceuticals is ranked #313 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Satish Ramanlal Mehta and family are #181 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Pune, under CIN L24231PN1981PLC024251. Its GSTIN is 05AAACE4574C1Z1 (Uttarakhand). The company holds 29 GST registrations, of which 21 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 544210 and NSE: EMCURE.

The company has an authorised share capital of ₹250 Cr and a paid-up capital of ₹189.71 Cr. It was formerly known as Emcure Pharmaceuticals Private Limited. It is led by directors including Satish Ramanlal Mehta (Managing Director) and Mukund Keshao Gurjar (Whole-Time Director).

Its last annual general meeting (AGM) was held on 21 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Bt Park, Pune, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹9,203.54 Cr, a growth of 16.6% compared to the previous year. For the same year it recorded a net profit of ₹945.24 Cr (net margin 10.3%) and EBITDA of ₹1,714.38 Cr (EBITDA margin 18.6%). The net worth stands at ₹4,950.03 Cr (up 11.3% YoY). Total assets are valued at ₹6,608.99 Cr (up 9.8% YoY).

The company has about 6,877 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 3 brands: Chiral Emcure, Emcure and Gennova. As per MCA filings, the company has open charges of ₹1,507.01 Cr and satisfied charges of ₹7,360.74 Cr on record. Court records list 370 cases involving the company, including 229 filed by the company and 142 filed against it; 52 cases are pending. The company has 36 deals on record (21 secondary share transfers, 8 market trades, 5 funding rounds), with disclosed funding of ₹238.75 Cr; the latest was in June 2026. Its 4 peer companies in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 2 larger and 2 smaller; the largest is Divi's Laboratories Limited with revenue of ₹9,712 Cr. The company has 10 MSME Form 1 returns on record between 2019 and 2024, listing 2,012 overdue payments to 257 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website emcure.co.in.

Company details

CIN L24231PN1981PLC024251
Registration Number 024251
Incorporation Date 16 April 1981
ROC Pune
Listing Status Listed - Listed on NSE (EMCURE); Listed on BSE (544210)
Company Status Active
Date of Last AGM 21 September 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Emcure Pharmaceuticals has one previous CIN (Corporate Identification Number): U24231PN1981PLC024251. The current CIN is L24231PN1981PLC024251, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24231PN1981PLC024251Current
U24231PN1981PLC024251Previous
Key People
Satish Ramanlal Mehta Managing Director Mukund Keshao Gurjar Whole-Time Director Sunil Rajanikant Mehta Whole-Time Director

Recognitions & Rankings of Emcure Pharmaceuticals

Fortune India 500 2025 edition
Rank#313
Total income
₹8,232 Cr
Profit
₹681 Cr
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#232
Valuation
₹25,580 Cr
2023 #237 2022 #202 2021 #223
Stock market indices
Nifty 500 BSE 500

Contact details

Emcure Pharmaceuticals Limited's registered office is in Pune, Maharashtra. Its website is emcure.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    emcure.co.in
  • Social Media
  • Registered Address
    Plot No. P – 1 & P – 2 It – Bt Park, Phase – II M.I.D.C., Pune, Maharashtra, India – 411057
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers

To see the full contact details of Emcure Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Emcure Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Emcure Pharmaceuticals operates multiple associated brands including Chiral Emcure, Emcure, and Gennova. Each brand links to its own profile.

BrandDescriptionWebsite
Chiral Emcure
Research and manufacturing of pharmaceutical APIs, formulations, and biotechnology products globally.chiralemcure.com
Emcure
Developer, manufacturer, and markets a broad range of pharmaceutical productsemcure.com
Gennova
Biotherapeutics for life-threatening diseases are developed, produced, and commercialized.gennova.bio

Business activity

The main business activity of Emcure Pharmaceuticals is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Emcure Pharmaceuticals Limited, buy the company report.

Financials of Emcure Pharmaceuticals Limited

FY 2025-26 filings available

Emcure Pharmaceuticals Limited reported revenue of ₹9,203.54 Cr (up 16.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,204 Cr
+16.6% YoY
EBITDA
₹1,714 Cr
+17.5% YoY
Profit After Tax
₹945 Cr
+48.3% YoY
Net Worth
₹4,950 Cr
+11.3% YoY
Total Assets
₹6,609 Cr
+9.8% YoY
Total Debt
₹1,521 Cr
+48.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Profit before tax1,287971727747973652105
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Balance sheet
Total assets6,6096,0205,8115,0894,4454,9664,686
Net worth4,9504,4462,9522,5011,9882,2731,912
Total debt1,5211,0232,3352,3342,2172,3102,327
Cash & bank148165232458313524164
Net working capital2,7072,3872,1022,2921,8481,9151,429
Cash flow
Cash from operations9448521,097747768704500
Cash from investing(1,175)(96.05)(715)(468)(574)(256)(168)
Cash from financing343(814)(164)(145)(152)(189)(301)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,8202,5802,4702,3632,2702,1012,1161,963
Revenue growth (YoY)+24.3%+22.9%+16.7%+20.4%+13.4%+15.7%--
Other income3.252.0714.291.853.123.704.453.90
EBITDA588532480455475413392355
EBITDA margin+20.8%+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%
Depreciation11011010610510599.4696.8496.81
Interest35.5831.5446.4037.9832.5426.7639.0331.78
Profit before tax446394341314341291261230
Tax12110197.4482.4290.0575.9763.3773.83
Net profit325292244231251215197156
EPS (₹)17.1415.5012.8412.1612.8510.929.978.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Profit before tax944428200212616557225
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
Balance sheet
Total assets5,3723,9383,5933,6673,4264,0113,202
Net worth3,7113,0241,9351,8421,7132,3021,915
Total debt1,5978571,5951,7731,5791,6651,243
Cash & bank16.8813.8032.1214147.8826139.22
Net working capital1,5031,0089881,2201,2741,3921,170
Cash flow
Cash from operations424558585505428775385
Cash from investing(947)(438)(173)(271)(394)(836)(169)
Cash from financing526(49.25)(288)(54.52)(343)30.97(45.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,6681,4511,4681,4181,2611,0971,2781,029
Revenue growth (YoY)+32.3%+32.3%+14.8%+37.9%+14.1%+13.0%--
Other income33.5425.0334.5213822.7521.5222.4019.41
Total expenses1,2721,1111,0961,1471,0368721,034904
EBITDA396340372271225224245124
EBITDA margin+23.8%+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%
Depreciation65.0163.1763.0462.1461.7459.8256.9156.65
Interest32.4232.7836.8733.1527.7120.5424.0719.93
Profit before tax33226930631415816618667.24
Tax83.9568.5772.5755.5140.2742.8846.4917.05

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,8202,5802,4702,3632,2702,1012,1161,963
Revenue growth (YoY)+24.3%+22.9%+16.7%+20.4%+13.4%+15.7%--
Other income3.252.0714.291.853.123.704.453.90
EBITDA588532480455475413392355
EBITDA margin+20.8%+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%
Depreciation11011010610510599.4696.8496.81
Interest35.5831.5446.4037.9832.5426.7639.0331.78
Profit before tax446394341314341291261230
Tax12110197.4482.4290.0575.9763.3773.83
Net profit325292244231251215197156
EPS (₹)17.1415.5012.8412.1612.8510.929.978.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
Other income13172.7956.9945.9163.4733.8882.31
Total expenses7,4896,4385,4384,8114,5254,0104,448
Employee cost1,5521,4461,2921,1171,0129031,106
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Depreciation415384312260245250321
Interest144176237214176155257
Profit before tax1,287971727747973652105
Tax3462642001852702334.73
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus4,7604,2572,7712,3201,8072,0921,731
Shareholders' funds (net worth)4,9504,4462,9522,5011,9882,2731,912
Minority interest26.6419516914912794.9972.41
Secured loans1,2047301,7231,8831,8001,9552,513
Unsecured loans317293612452418355(187)
Total debt1,5211,0232,3352,3342,2172,3102,327
Total liabilities6,6096,0205,8115,0894,4454,9664,686
Assets
Gross block5,9525,4385,0523,8023,4723,2493,523
Net block3,3193,1973,1252,1472,0442,1882,382
Capital work in progress273177159411320302485
Investments19.7095.3831825.0025.000.000.00
Inventories2,3981,9321,5251,3831,4491,5141,173
Sundry debtors2,5632,0021,8591,6481,3091,4751,145
Cash & bank balances148165232458313524164
Loans & advances504380344346353204221
Total current assets5,6124,4803,9603,8363,4243,7172,703
Total current liabilities2,9052,0931,8581,5441,5761,8021,274
Net working capital2,7072,3872,1022,2921,8481,9151,429
Total assets6,6096,0205,8115,0894,4454,9664,686
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(14.31)43.99(175)(308)(350)(609)(641)
Net cash from operating activities9448521,097747768704500
Net cash from investing activities(1,175)(96.05)(715)(468)(574)(256)(168)
Net cash from financing activities343(814)(164)(145)(152)(189)(301)
Net change in cash112(58.30)21913441.8725931.86
Closing cash148165232458313524164
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
EBITDA growth+17.6%+19.6%+3.8%-11.7%+30.0%+70.4%-
PBT growth+32.5%+33.6%-2.7%-23.2%+49.2%+519.1%-68.1%
Net income growth+48.3%+26.6%-6.2%-19.0%+57.2%+165.2%-
Revenue CAGR (3Y)+15.4%+10.5%+9.8%+5.8%+7.5%--
EBITDA CAGR (3Y)+13.4%+3.1%+6.0%+25.1%+28.6%--
Profitability & leverage
Net income margin+10.2%+9.0%+7.9%+9.4%+12.0%+8.3%+2.0%
Return on capital employed+23.1%+20.0%+18.2%+20.8%+25.0%+21.1%+10.4%
Return on net worth+20.0%+19.1%+19.4%+25.0%+33.0%+20.1%+9.4%
Debt / equity0.270.450.861.011.061.111.19
Long-term debt / equity0.100.190.340.380.360.390.42
Interest cover11.0616.3626.1423.3516.2220.0491.77
Efficiency & per share
Fixed asset turnover1.621.511.501.651.741.491.52
Inventory turnover4.254.574.584.233.953.754.39
Debtors turnover4.034.093.804.054.213.844.77
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)261.09234.65162.97138.30109.90125.68105.72
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,6681,4511,4681,4181,2611,0971,2781,029
Revenue growth (YoY)+32.3%+32.3%+14.8%+37.9%+14.1%+13.0%--
Other income33.5425.0334.5213822.7521.5222.4019.41
Total expenses1,2721,1111,0961,1471,0368721,034904
EBITDA396340372271225224245124
EBITDA margin+23.8%+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%
Depreciation65.0163.1763.0462.1461.7459.8256.9156.65
Interest32.4232.7836.8733.1527.7120.5424.0719.93
Profit before tax33226930631415816618667.24
Tax83.9568.5772.5755.5140.2742.8846.4917.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
Other income312142138125133112138
Total expenses4,2463,7593,0652,6752,5932,4291,996
Employee cost821782706649604551545
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Depreciation247225205179166156155
Interest118113166167145123137
Profit before tax944428200212616557225
Tax21111139.0852.2717013749.47
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus3,5212,8351,7541,6611,5322,1211,734
Shareholders' funds (net worth)3,7113,0241,9351,8421,7132,3021,915
Secured loans8102511,4161,6691,5791,5971,191
Unsecured loans7876061801040.0067.1852.59
Total debt1,5978571,5951,7731,5791,6651,243
Total liabilities5,3723,9383,5933,6673,4264,0113,202
Assets
Gross block3,3233,1542,9532,4722,0312,0131,762
Net block1,7541,7591,7181,4331,1511,2781,166
Capital work in progress12299.11106253239192326
Investments1,424678684690563864408
Inventories1,2071,038770710730622444
Sundry debtors1,5351,1911,1031,0541,0099991,138
Cash & bank balances16.8813.8032.1214147.8826139.22
Loans & advances283218218234354334186
Total current assets3,0412,4602,1232,1402,1422,2151,808
Total current liabilities1,5381,4521,135919868824637
Net working capital1,5031,0089881,2201,2741,3921,170
Total assets5,3723,9383,5933,6673,4264,0113,202
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(17.53)(88.91)(213)(393)(84.29)(54.35)(225)
Net cash from operating activities424558585505428775385
Net cash from investing activities(947)(438)(173)(271)(394)(836)(169)
Net cash from financing activities526(49.25)(288)(54.52)(343)30.97(45.87)
Net change in cash2.5171.38124180(309)(29.94)170
Closing cash16.8813.8032.1214147.8826139.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
EBITDA growth+60.1%+44.1%+0.1%-45.6%+9.6%+91.2%-
PBT growth+120.8%+114.0%-5.9%-65.6%+10.6%+148.1%-39.3%
Net income growth+180.4%+65.1%-1.5%-63.1%+3.0%+108.6%-
Revenue CAGR (3Y)+19.1%+9.0%+3.5%+9.4%+11.4%--
EBITDA CAGR (3Y)+32.1%-7.8%-15.8%+4.5%+14.1%--
Profitability & leverage
Net income margin+14.0%+7.2%+4.6%+5.2%+13.2%+13.3%+7.4%
Return on capital employed+22.8%+14.4%+10.1%+10.7%+20.5%+18.9%+13.1%
Return on net worth+21.8%+12.8%+8.5%+9.0%+22.3%+20.0%+11.3%
Debt / equity0.360.490.890.940.790.690.67
Long-term debt / equity0.220.240.340.340.290.280.26
Interest cover15.7528.3772.9365.7323.0821.6861.18
Efficiency & per share
Fixed asset turnover1.621.441.291.381.731.671.43
Inventory turnover4.674.854.734.315.015.925.06
Debtors turnover3.853.823.243.013.372.952.32
EPS (₹)38.6616.748.888.8524.7123.259.69
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)195.72159.61106.82101.8494.69127.27105.86

To see the full year-wise statements and ratios of Emcure Pharmaceuticals Limited, buy the company report.

Board of directors of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals has 10 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Shailesh Kripalu Ayyangar
Also directs: Gennova Biopharmaceuticals Limited, Zuventus Healthcare Limited, Shaily Engineering Plastics Limited and 2 more
Director16 Apr 20215 Years 6 MonthsCurrent
Satish Ramanlal Mehta
Also directs: Emcutix Biopharmaceuticals Limited, Zuventus Healthcare Limited
Managing Director16 Apr 198145 Years 6 MonthsCurrent
Mukund Keshao GurjarWhole-Time Director23 Jul 200125 Years 3 MonthsCurrent
Vijay Keshav Gokhale
Also directs: Zuventus Healthcare Limited, Kpit Technologies Limited
Director16 Apr 20215 Years 6 MonthsCurrent
Vidya Rajiv Yeravdekar
Also directs: Bajaj Holdings & Investment Limited., Mahratta Chamber of Commerce Industries and Agriculture, Apical Hospitality Services Private Limited. and 3 more
Director16 Apr 20215 Years 6 MonthsCurrent
Sunil Rajanikant Mehta
Also directs: Gennova Biopharmaceuticals Limited
Whole-Time Director05 Jun 201313 Years 5 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Emcure Pharmaceuticals Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Divi's Laboratories Limited₹9,712 Cr (FY 2025)19.0%Hyderabad, Telangana, India
Emcure Pharmaceuticals Limitedthis company₹9,203.54 Cr (FY 2026)₹945.24 Cr10.3%16.6%6,877Pune, Maharashtra, India
Ipca Laboratories Limited₹9,032.39 Cr (FY 2025)15.0%Mumbai, Maharashtra, India
Jubilant Pharmova Limited₹7,291.3 Cr (FY 2025)8.0%Uttar Pradesh, India
Alembic Pharmaceuticals Limited₹6,714.63 Cr (FY 2025)7.0%Vadodara, Gujarat, India

To see the full peer comparison of Emcure Pharmaceuticals Limited, buy the company report.

Auditor

Emcure Pharmaceuticals Limited is audited by B S R & Co. Llp for the financial year 2025.

Auditor firmFinancial yearFirm registration number
B S R & Co. LlpFY 2025101248W /W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 77.80%, foreign institutional investors hold 4.90%, domestic institutional investors hold 8.40% and retail and other public shareholders hold 8.90%.

Promoters: 77.80%DII (Domestic Institutional): 8.40%FII (Foreign Institutional): 4.90%Retail & Others: 8.90%
Sep 2026
QUARTER
77.80% Promoters
8.40% DII (Domestic Institutional)
4.90% FII (Foreign Institutional)
8.90% Retail & Others
Promoter holding - history
Now 77.80% · Sep 2026High 77.90% · Dec 2025Low 77.80% · Sep 2026
76%76.8%77.5%78.3%79%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 77.90%Mar 2026: 77.90%Jun 2026: 77.90%Sep 2026: 77.80%77.90%77.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters77.80%77.90%77.90%77.90%
Public22.20%22.10%22.10%22.10%

Charges & borrowings

Open charges
₹1,507.01 Cr
Satisfied charges
₹7,360.74 Cr
Breakdown by lending institutions
Others₹1,081.00 Cr
Axis Bank Limited₹276.01 Cr
Citi Bank N.A.₹150.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
17 Jun 2026101322472Axis Bank Limited₹187 CrOpen
18 Dec 2025101205811Citi Bank N.A.₹150 CrOpen
19 Sep 2025101168650Others₹100 CrOpen
12 Jun 2025101117779Others₹250 CrOpen
15 May 2024100930339Others₹100 CrOpen

To see the full charge records of Emcure Pharmaceuticals Limited, buy the company report.

Total charge records: 133 View all charges

Deals & funding

Emcure Pharmaceuticals Limited has 36 deals on record (21 secondary share transfers, 8 market trades, 5 funding rounds), with disclosed funding of ₹238.75 Cr; the latest was in June 2026.

Total deals
36
Secondary share transfers
21
Market trades
8
Funding rounds
5
IPO
1
Disclosed funding
₹238.75 Cr

Deals on record (5 of 36)

WhenDealAmountParties
Jun 2026Market trade₹352.4 CrBuyer: HDFC Life Insurance Company Limited , Axis Mutual Fund, Aditya Birla Sun Life Mutual Fund
Seller: Bc Investments Iv Limited
Jun 2026Market trade₹352.4 CrSeller: Bc Investments Iv Limited
Nov 2025Market trade₹609.99 CrSeller: Bc Investments Iv Limited
Jul 2025Market trade₹562.7 CrSeller: Bc Investments Iv Limited
Jul 2024IPO₹1,952.03 CrInvestors: IPO - Emcure Pharmaceuticals Limited, Icici Prudential Pharma Healthcare & Diagnostics (P.H.D.) Fund, Nomura India Investments Fund Mother Fund
Seller: Bain Capital Private Equity, 3 individuals

To see the full deal history of Emcure Pharmaceuticals Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Emcure Pharmaceuticals Limited was last rated by Care on 07 Jan 2022.

Rating agencyRated onRating
Care07 Jan 2022

To see the full credit ratings and regulatory alerts of Emcure Pharmaceuticals Limited, buy the company report.

MSME payment delays

Emcure Pharmaceuticals Limited has 10 MSME Form 1 returns on record between 2019 and 2024, listing 2,012 overdue payments to 257 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 257)

SupplierAmount dueDue sinceReported on
Samarika Pharma Solutions LLP
an individual supplier
an individual supplier
an individual supplier
an individual supplier

To see the full MSME payment records of Emcure Pharmaceuticals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Emcure Pharmaceuticals has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Gennova Biopharmaceuticals LimitedU24231PN2001PLC016253
Zuventus Healthcare LimitedU85320PN2002PLC018324

To see the full group structure of Emcure Pharmaceuticals Limited, buy the company report.

Employees & EPFO

Emcure Pharmaceuticals Limited has a workforce of 6,877 employees on its EPFO records as of Mar 03, 2025, across 10 active EPFO establishments.

Employee count
6,877
Active EPFO establishments
10
Employee growth
5.12%

GST

Emcure Pharmaceuticals has 29 GST registrations: 21 active and 8 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
29
Active
21
Cancelled / inactive
8
GSTINStateStatusRegistered on
05AAACE4574C1Z1UttarakhandActive01 Jul 2017
06AAACE4574C1ZZHaryanaActive01 Jul 2017
07AAACE4574C1ZXDelhiActive01 Jul 2017
08AAACE4574C1ZVRajasthanActive01 Jul 2017

To see the full GST registrations and return filing status of Emcure Pharmaceuticals Limited, buy the company report.

Recent activity

Emcure Pharmaceuticals Limited has 52 board changes on record since 1981: 31 appointments and 21 cessations. The latest: Raman Pillai Raghu Kumar was appointed as Director on 06 Aug 2026.

AGM
Emcure Pharmaceuticals Limited last Annual general meeting of members was held on 21 Sep 2026 as per latest MCA records.
Appointed
Raman Pillai Raghu Kumar was appointed as Director.
Charges
A charge with Others of Rs. 250.00 Cr registered on 07 Sep 2021 with Charge ID 100480067 was modified on 31 Jul 2026.
Charges
A charge registered on 01 Jul 2020 via Charge ID 100347650 with Others was fully satisfied on 31 Jul 2026.
Charges
A charge with Others of Rs. 6.00 Cr registered on 07 Aug 2019 with Charge ID 100280185 was modified on 31 Jul 2026.
Charges
A charge registered on 19 Mar 2018 via Charge ID 100161882 with Axis Bank Limited was fully satisfied on 31 Jul 2026.
Charges
A charge registered on 23 Jan 2018 via Charge ID 100151755 with Axis Bank Limited was fully satisfied on 31 Jul 2026.
Charges
A charge with Axis Bank Limited of Rs. 30.00 Cr registered on 29 Jul 2016 with Charge ID 100042541 was modified on 31 Jul 2026.
Charges
A charge with Axis Bank Limited of Rs. 55.00 Cr registered on 08 Jul 2010 with Charge ID 10228273 was modified on 31 Jul 2026.
Charges
A charge registered on 23 Jun 2021 via Charge ID 100459524 with Axis Bank Limited was fully satisfied on 27 Jul 2026.
Charges
A charge registered on 03 Jul 2021 via Charge ID 100459526 with Axis Bank Limited was fully satisfied on 20 Jul 2026.
Charges
A charge with Axis Bank Limited amounted to Rs. 187.00 Cr with Charge ID 101322472 was registered on 17 Jun 2026.

321 earlier events are in the company report.

News

EMCURE: Q2 CONS NET PROFIT 3.3B RUPEES VS 2.44B (YOY)
03 Nov 2026 · Exchange Update
EMCURE: Q2 REVENUE 28B RUPEES VS 22.7B (YOY)
03 Nov 2026 · Exchange Update
EMCURE: Q2 EBITDA 5.87B RUPEES VS 4.7B (YOY); Q2 EBITDA MARGIN 20.84% VS 20.94% (YOY)
03 Nov 2026 · Exchange Update
EMCURE: Rs. 28.98 Crores NSE Block Trade; for ~ 152,544 Shares, at Rs. 1900.10
06 Oct 2026 · Exchange Update
Emcure Pharmaceuticals Ltd.: Rs. 17.47 Crores NSE Block Trade; for ~ 90,289 Shares, at Rs. 1934.50
16 Sep 2026 · Exchange Update

From our blog

Frequently asked questions

Emcure Pharmaceuticals is an active public limited company based in Pune, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 April 1981 (45+ years old) and is registered under CIN L24231PN1981PLC024251. Listed on BSE: 544210 and NSE: EMCURE.

Emcure Pharmaceuticals reported revenue of ₹9,203.54 Cr for FY 2025-26 (up 16.6% YoY) based on consolidated financials.

Emcure Pharmaceuticals has 10 current directors:

The latest financial statements of Emcure Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 21 September 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Emcure Pharmaceuticals is 05AAACE4574C1Z1, registered in Uttarakhand. The company has 29 GST registrations in all, of which 21 are active and 8 are cancelled or inactive. Other active GSTINs include 06AAACE4574C1ZZ (Haryana), 07AAACE4574C1ZX (Delhi), 08AAACE4574C1ZV (Rajasthan).

The CIN (Corporate Identification Number) of Emcure Pharmaceuticals is L24231PN1981PLC024251. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Emcure Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 544210) and NSE (symbol: EMCURE).

Emcure Pharmaceuticals has 370 court cases on record: 229 filed by the company and 142 filed against it. 52 are pending. Most are in the high courts.

Emcure Pharmaceuticals was incorporated on 16 April 1981, making it 45+ years old. It is registered with the Registrar of Companies, Pune.

Emcure Pharmaceuticals has 36 deals on record (21 secondary share transfers, 8 market trades, 5 funding rounds), with disclosed funding of ₹238.75 Cr; the latest was in June 2026.

The peers of Emcure Pharmaceuticals by revenue are Divi's Laboratories Limited, Ipca Laboratories Limited, Jubilant Pharmova Limited, Alembic Pharmaceuticals Limited, all in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Raman Pillai Raghu Kumar was appointed as Director on 06 Aug 2026. Chinnadharavaram Sundaresan Muralidharan was appointed as Director on 01 Apr 2026. Samonnoi Sajani Banerjee ceased to be Director on 23 Nov 2024. Emcure Pharmaceuticals has 52 board changes on record in total.